



Acarix to Release Q2 2024 Results with a Live Webcast on August 22, 2024

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, will publish its second-quarter results on Thursday, August 22, 2024, at 08.00 am (CET). Additionally, a live webcast will be held at 14.00 pm (CET) on the same day, during which President and CEO Aamir Mahmood will present the report.

The presentation will conclude with a Q&A session with CEO Aamir Mahmood, CFO Christian Lindholm, and Carnegie analysts, allowing attendees to ask the company questions via the form on the live page. The webcast will be available at: <https://youtube.com/live/FyDlqLYDoLI?feature=share>

For more information contact:

Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Acarix to Release Q2 2024 Results with a Live Webcast on August 22, 2024](#)